Cellino Co-Founder Marinna Madrid Takes Expanded Role as Chief Product and Regulatory Officer, Joins Board
Event summary
- Dr. Marinna Madrid, co-founder of Cellino, expands role to Chief Product and Regulatory Officer and joins the company's Board of Directors.
- Madrid led Cellino to secure FDA's Advanced Manufacturing Technology (AMT) designation in May 2025, a first for iPSC-based technology.
- Cellino's platform uses closed-loop AI-based systems for real-time monitoring, analysis, and optimization of cell manufacturing.
- Madrid's expertise spans physics, engineering, AI, laser optics, robotics, and stem cell biology.
The big picture
Cellino's expansion of Dr. Marinna Madrid's role underscores the growing intersection of AI and biomanufacturing, a trend reshaping the regenerative medicine sector. Madrid's regulatory leadership and technical expertise position Cellino at the forefront of this convergence, potentially setting new standards for AI-driven cell therapy production. The company's FDA AMT designation highlights the strategic importance of its AI-integrated approach in gaining regulatory approval and market acceptance.
What we're watching
- Regulatory Influence
- How Madrid's engagement with global regulatory bodies will shape AI integration in cell therapy manufacturing.
- Technological Scaling
- The pace at which Cellino's AI-driven platform can achieve industrial-scale precision and reliability in cell production.
- Market Adoption
- Whether Cellino's AMT designation will accelerate the commercialization of its AI-driven cell therapy manufacturing.
Related topics